CAS: 4215-80-9; Triphenylsilanamine

上下游产品

Triphenylsilyl chloride ammonia triphenylhydroxysilane triphenylsilyl bromideBis(trimethylsilyl)triphenylsilylamin 77H68O4Si4C77H68O4Si4 triphenylsilyl hydroperoxide bis(triphenylsilyl) peroxide

三苯基氯硅烷置于lithium Amide体系中,用 四氢呋喃 作为反应溶剂,以80%的收率获得产物三苯甲硅烷基
参考文献:具有立体可调双(酰胺基)甲硅烷基配体的低配位亚甲基和亚锡杂环
标题:具有立体可调双(酰胺基)甲硅烷基配体的低配位亚甲基和亚锡杂环
摘要:已经制备了一系列单体杂环金属亚甲基[{ I Pr 2 Si(nr)2 } M:](m = Ge和sn; R = Dipp = 2,6-Ipr 2 C 6 H 3或siph 3).初步的原子转移化学包括具有硫族元素源me 3 No和s 8的新的低价亚甲基苯,反应生成了相应的二聚氧-硫键配合物(例如[{ I Pr 2 Si(ndipp)2 } Ge(μ-E)] 2; E = O和s).对金属亚甲基及其氧化产物的结构分析表明,在nsin螯合物中并入伞形三芳基甲硅烷基(siph 3)相对于dipp基团,对第14基团中心提供了额外的空间保护.将可空间修饰的-Siar 3(ar =芳基)单元作为双(酰胺基)配体阵列的一部分包括在内,代表了该领域的一种新方法,并且在实现越来越高的空间体积方面具有可观的前景.
DOI:10.1021/ic101485A

专利信息

专利号:EP-3412666-A1
优先权日:2017-06-07
标 题:Process and intermediates for the preparation of bcl-2 inhibitors including venetoclax through reductive amination
发明人：GREGG BRIAN THOMAS; GEISS WILLIAM BERT; HERR ROBERT JASON
权利人:ALBANY MOLECULAR RES INC
摘要:The invention relates to a process for the preparation of compounds of formula (I), which are useful intermediates in the synthesis of Venetoclax and structurally related compounds, by reductive amination of a compound of formula (II).

专利号:US-4730074-A
优先权日:1986-12-31
标 题 :Vapor phase alcoholysis of aminosilanes and carbamatosilanes
发明人：LEWIS KENRICK M; MENDICINO FRANK D; CHU NAN S
权利人:UNION CARBIDE CORP
摘要:A vapor phase process for the synthesis of alkoxysilanes of the general formula HSi(OR'') x (R') 3-x which comprises reacting n (a) a silane of the general formula n n HSi(NRR').sub.x (R').sub.3-x n n wherein R, R' and R' are individually hydrogen or an aryl or alkyl group optionally containing unsaturation, each having from one to eight carbon atoms inclusive, and where R' may also be an alkoxy or carbamato group and where x has a value of from one to three; with n (b) an alcohol of the general formula n n R''OH n n wherein R'' is an aryl group, or an alkyl group optionally containing unsaturation, each having from one to twenty carbon atoms inclusive and optionally substituted said reaction taking place in the presence of n (c) a catalyst n in which both the silane and the alcohol are present in gaseous form in a stoichiometric ratio of 0.4 to 1.05 moles of alcohol per mole of silicon-nitrogen bonds and where said catalyst is present in an amount from 0.01 to 10 mole percent of the silicon-nitrogen bonds.

专利号:US-9469609-B2
优先权日:2006-12-21
标 题:Synthesis of pyrrolidine compounds
发明人：ALIMARDANOV ASAF R; KRISHNAN LALITHA; ZHOU MAOTANG; WANG TING-ZHONG; REN JIANXIN; CONSIDINE JOHN LEO; WU CHARLES C; BRAZZILLO JASON; RAVEENDRANATH PANOLIL; SUTHERLAND KAREN; MIRMEHRABI MAHMOUD; DESHMUKH SUBODH S
权利人:ZEALAND PHARMA AS
摘要:Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.

专利号:WO-2022049567-A3
优先权日:2021-04-28
标题:Synthesis and in silico studies of novel anti-sars-cov sulfonamides as potential inhibitors against covid-19 protein target: sars-cov-2 main protease (m pro )
发明人：AL-SEHEMI ABDULLAH G; CHINNAM SAMPATH; PANNIPARA MEHBOOBALI; YALLUR BASAPPA C; CHIGURUPATI SRIDEVI; GOWDA B H JASWANTH; PAUL KARTHIKA; SHIVANNA CHANDAN RAVANDUR; VARDHARAJULA VENKATA RAMAIAH
权利人:AL SEHEMI ABDULLAH G; CHINNAM SAMPATH; PANNIPARA MEHBOOBALI; YALLUR BASAPPA C; CHIGURUPATI SRIDEVI; GOWDA B H JASWANTH; PAUL KARTHIKA; SHIVANNA CHANDAN RAVANDUR; VARDHARAJULA VENKATA RAMAIAH
摘要:A cluster of pneumonia cases and COVID-19 pandemic that started in Wuhan, China, was caused by novel beta coronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation requires the activity of the main viral protease (Mpro) and thereby, inhibition stops the advancement of the disease. The current invention delivers a potential anti-viral drug candidates docked against COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E.Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of -14.00 kcal/mol.

专利号:US-2008188545-A1
优先权日:2006-12-21
标题 :Synthesis of pyrrolidine compounds

专利号:US-9139596-B2
优先权日:2012-03-30
标 题:Cyclic prodrugs of duocarmycin analogs
发明人：BOGER DALE L
权利人:SCRIPPS RESEARCH INST
摘要:The invention provides prodrugs of DNA-reactive analogs of duocarmycin and CC-1065 anticancer agents, wherein a cyclic prodrug form, such as carbamate, thionocarbamate, or carbamimidate, can be hydrolyzed by the patient in vivo to yield a respective bioactive agent comprising a DNA-alkylating moiety and a binding/targeting moiety. The DNA-reactive moiety is a γ-spirocyclohexenone fused to a heterocyclyl group which can be produced by endogenous hydrolysis of a cyclic carbamate prodrug of the invention. The cyclic carbamate prodrug produces no residual byproduct during activation in vivo. Methods of synthesis and biological methods and data are also provided.